NCT05720260View on ClinicalTrials.gov

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

PHASE2RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

January 17, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

January 31, 2027

Conditions
Premenopausal Breast CancerMetastatic Breast CancerER Positive Breast Cancer
Interventions
DRUG

Goserelin

Hormone therapy

DRUG

Fulvestrant

Hormone therapy

DRUG

Capivasertib

AKT inhibitor

DRUG

Durvalumab

immunotherapy

Trial Locations (1)

100

RECRUITING

Department of Oncology, National Taiwan University Hospital, Taipei

All Listed Sponsors
lead

National Taiwan University Hospital

OTHER